Blood G6PDH (Quantitative) at Chughtai Lab

Blood G6PDH (Quantitative) at Chughtai Lab

The Blood G6PDH (Quantitative) test is a highly specialized diagnostic laboratory investigation designed to measure the precise enzymatic activity of Glucose-6-Phosphate Dehydrogenase (G6PD) in red blood cells. Glucose-6-Phosphate Dehydrogenase is a vital cytosolic enzyme found in all human cells, but it plays an exceptionally critical role in mature erythrocytes (red blood cells). Because red blood cells lack mitochondria and other organelles, they rely solely on the pentose phosphate pathway (hexose monophosphate shunt) to generate nicotinamide adenine dinucleotide phosphate (NADPH). This coenzyme is essential for maintaining glutathione in its reduced state, which acts as the primary cellular defense mechanism against oxidative stress and reactive oxygen species. When G6PD activity is deficient, red blood cells become highly susceptible to oxidative damage, leading to premature destruction, intravascular hemolysis, and acute or chronic hemolytic anemia.

At Chughtai Lab, one of Pakistan’s premier diagnostic networks, the Blood G6PDH (Quantitative) test is performed using advanced quantitative kinetic enzyme assays. Unlike qualitative screening tests that only provide a positive or negative result, the quantitative assay measures the exact level of enzyme activity, typically expressed in units per gram of hemoglobin (U/g Hb). This precise quantification is clinically invaluable for classifying the severity of G6PD deficiency according to the World Health Organization (WHO) guidelines, distinguishing between different genetic variants, and identifying heterozygous female carriers who may exhibit intermediate enzyme levels due to random X-chromosome inactivation (lyonization). The diagnostic value of this test is paramount in preventing life-threatening hemolytic crises, managing neonatal hyperbilirubinemia, and screening patients before initiating therapies with potent oxidizing medications.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is essential to ensure the clinical accuracy of the Blood G6PDH (Quantitative) test. Patients must adhere to the following guidelines prior to sample collection:

• Avoid Testing During Acute Hemolytic Episodes: Testing should ideally not be performed during or immediately after an active hemolytic crisis. During acute hemolysis, older red blood cells with lower enzyme levels are destroyed first, leaving behind a higher proportion of young red blood cells (reticulocytes) which naturally contain elevated levels of G6PD. This can lead to a falsely normal or elevated result, masking an underlying deficiency. It is generally recommended to wait 8 to 12 weeks after a hemolytic episode before testing.
• Post-Transfusion Delay: If the patient has recently received a blood transfusion, the test must be delayed for at least 3 months. A transfusion introduces donor red blood cells with normal G6PD levels into the patient’s circulation, which will yield a false-normal result.
• Medication Review: Patients must inform their healthcare provider and the laboratory staff of all medications, supplements, and herbal remedies they are taking. Certain oxidizing drugs, such as antimalarials (primaquine), sulfonamides, dapsone, and high-dose vitamin C, should be reviewed by the prescribing physician prior to testing.
• Dietary Restrictions: No fasting is required for this blood test. However, patients should avoid consuming fava beans (broad beans) prior to the test if they suspect G6PD deficiency, as this can trigger hemolysis.

During the Procedure

The Blood G6PDH (Quantitative) test requires a standard peripheral blood sample. The collection process is quick, safe, and performed by highly trained phlebotomists at Chughtai Lab:

• Patient Positioning: The patient is seated comfortably, and the phlebotomist identifies a suitable vein, typically the median cubital vein in the antecubital fossa of the arm.
• Sanitization: The skin over the selected vein is thoroughly cleansed with an antiseptic swab (70% isopropyl alcohol) and allowed to air dry to prevent contamination or hemolysis of the sample.
• Venipuncture: A sterile, single-use needle is inserted into the vein. A tourniquet may be applied briefly to the upper arm to make the vein more visible, but it is released promptly to prevent hemoconcentration.
• Sample Collection: Blood is drawn into a vacuum tube containing ethylenediaminetetraacetic acid (EDTA, lavender top) or heparin (green top) as an anticoagulant. These additives preserve the integrity of the red blood cells and the stability of the intracellular G6PD enzyme.
• Post-Collection Care: The needle is gently withdrawn, and immediate pressure is applied to the puncture site with a sterile cotton ball or gauze pad to prevent hematoma formation. A small adhesive bandage is applied. The entire procedure takes less than five minutes.
• Safety and Comfort: Chughtai Lab strictly adheres to international biosafety standards, utilizing sterile, disposable equipment for every patient to eliminate any risk of cross-contamination.

When is a Blood G6PDH (Quantitative) Performed?

Investigation of Neonatal Jaundice

Neonatal hyperbilirubinemia is a common clinical presentation where the Blood G6PDH (Quantitative) test is critical. Newborns with G6PD deficiency are at a significantly higher risk of developing severe, prolonged, or early-onset jaundice within the first 24 hours of life. If left undiagnosed and untreated, the rapid accumulation of unconjugated bilirubin can cross the blood-brain barrier, leading to bilirubin-induced neurologic dysfunction (BIND) or kernicterus, which causes permanent brain damage. Pediatricians routinely request this quantitative test for neonates exhibiting atypical jaundice, especially those with a family history of the deficiency or those belonging to high-risk ethnic groups.

Unexplained Hemolytic Anemia

Physicians request this test when investigating patients of any age who present with signs and symptoms of acute hemolytic anemia. These symptoms include sudden onset of fatigue, pallor, shortness of breath, tachycardia, dark tea-colored urine (hemoglobinuria), and scleral icterus (yellowing of the eyes). The quantitative assay helps confirm whether the hemolytic event was triggered by G6PD deficiency following exposure to an oxidative stressor, such as an infection, specific foods, or chemical agents.

Pre-Treatment Screening for Oxidizing Medications

Before prescribing medications known to induce oxidative stress in red blood cells, healthcare providers must screen patients for G6PD deficiency. Common culprit medications include primaquine and tafenoquine (used for the radical cure of Plasmodium vivax malaria), dapsone (used for leprosy and opportunistic infections), sulfamethoxazole-trimethoprim, rasburicase, and certain nitrofurans. Performing a quantitative G6PD test prior to therapy prevents severe, drug-induced intravascular hemolysis, ensuring patient safety and guiding alternative therapeutic selections.

Exposure to Dietary or Environmental Triggers

The test is indicated for individuals who experience sudden hemolytic symptoms after consuming fava beans (a condition historically known as favism) or after inhaling pollen from fava plants. It is also performed when hemolysis occurs after exposure to environmental oxidants, such as naphthalene (found in mothballs) or certain industrial chemicals. Identifying the deficiency allows patients to receive crucial counseling on avoiding these specific triggers to prevent future life-threatening episodes.

Family History of G6PD Deficiency

Because G6PD deficiency is an X-linked recessive genetic disorder, it is primarily expressed in males, while females are typically asymptomatic carriers. When a family member is diagnosed with G6PD deficiency, clinical guidelines recommend screening other family members, particularly male infants and female relatives of childbearing age. Quantitative testing is essential for females because qualitative screens often fail to detect intermediate enzyme levels in heterozygous carriers, who can still pass the mutated gene to their offspring or experience hemolysis under extreme oxidative stress.

What Does a Blood G6PDH (Quantitative) Detect?

The Blood G6PDH (Quantitative) test is highly sensitive and capable of detecting a wide range of clinical states, genetic variations, and physiological responses associated with enzyme activity. Specifically, the test detects:

• Severe Class I G6PD Deficiency: Extremely low enzyme activity (less than 10% of normal) associated with chronic, lifelong nonspherocytic hemolytic anemia, even in the absence of oxidative triggers.
• Class II G6PD Deficiency: Severe deficiency (less than 10% of normal activity) characterized by intermittent, acute hemolytic episodes triggered by infections, drugs, or fava beans (common in Mediterranean populations).
• Class III G6PD Deficiency: Moderate deficiency (10% to 60% of normal activity) where hemolysis is usually mild and self-limiting, occurring only under significant oxidative stress (common in the G6PD A- variant).
• Class IV Normal Activity: Normal enzyme levels (60% to 150% activity) indicating no deficiency and a low risk of oxidative hemolysis.
• Class V Increased Enzyme Activity: Exceptionally rare cases of elevated G6PD activity, which generally carry no negative clinical consequences.
• Heterozygous Carrier Status in Females: Intermediate enzyme levels (typically 30% to 80% of normal) resulting from mosaicism, where some red blood cells are deficient and others are normal.
• Hemizygous Deficiency in Males: Clear, markedly reduced enzyme levels in males, who carry only one X chromosome and thus fully express the genetic defect.
• Homozygous Deficiency in Females: Rare cases where a female inherits two mutated G6PD genes, resulting in severe enzyme deficiency comparable to affected males.
• False-Normal Levels During Reticulocytosis: The presence of young red blood cells (reticulocytes) which temporarily masks a deficiency during or immediately after an acute hemolytic crisis.
• Post-Transfusion Interference: Falsely normal enzyme activity caused by the presence of transfused normal donor red blood cells in the patient’s circulation.
• Drug-Induced Hemolysis Susceptibility: High vulnerability to severe hemolytic reactions if exposed to oxidizing agents like primaquine or dapsone.
• Favism Susceptibility: The physiological basis for acute hemolytic reactions following the ingestion of fava beans.
• Infection-Triggered Hemolytic Risk: Increased risk of red blood cell destruction during acute bacterial or viral infections, which generate endogenous oxidants.
• Neonatal Hyperbilirubinemia Risk: The underlying cause of severe neonatal jaundice due to impaired bilirubin conjugation and increased erythrocyte destruction.
• Congenital Nonspherocytic Hemolytic Anemia (CNSHA): Chronic anemia from birth caused by unstable G6PD variants that degrade rapidly within the red blood cell.
• G6PD Mediterranean Variant: A specific severe mutation characterized by very low enzyme stability and activity.
• G6PD A- Variant: A common moderate mutation where the enzyme is moderately stable but degrades faster than normal as red blood cells age.
• G6PD Canton Variant: A common severe mutation prevalent in Asian populations.
• Impaired Pentose Phosphate Pathway Function: Decreased cellular capacity to generate NADPH, leading to compromised cellular antioxidant defenses.
• Heinz Body Formation Susceptibility: Propensity for denatured hemoglobin to precipitate within red blood cells under oxidative stress.
• Intravascular Hemolysis Propensity: Risk of red blood cells lysing directly within the bloodstream, releasing free hemoglobin.
• Extravascular Hemolysis Propensity: Risk of damaged red blood cells being prematurely cleared and destroyed by macrophages in the spleen and liver.
• Splenomegaly Risk: Potential for splenic enlargement due to the chronic or acute clearance of damaged, rigid red blood cells.
• Hemoglobinuria Risk: Potential for free hemoglobin to pass into the urine, causing dark, tea-colored urine and potential acute kidney injury.
• Decreased Haptoglobin Levels: Depletion of the transport protein haptoglobin as it binds to free hemoglobin released during hemolysis.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is widely recognized for its highly efficient laboratory operations and rapid turnaround times. The Blood G6PDH (Quantitative) test is processed using fully automated, high-throughput analyzers that ensure both speed and precision. Typically, the quantitative G6PD report is completed and verified by a consultant pathologist within 24 to 48 hours of sample collection.

Patients can access their diagnostic reports seamlessly through multiple digital channels provided by Chughtai Lab. Once the report is verified, an automated SMS notification containing a direct download link is sent to the patient’s registered mobile number. Reports can also be accessed, viewed, and downloaded in PDF format via the official Chughtai Lab website portal or through the user-friendly Chughtai Healthcare Mobile App. For patients who prefer physical copies, reports can be collected directly from any Chughtai Lab collection center or delivered to their home upon request.

Blood G6PDH (Quantitative) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
G6PD Enzyme Activity (Adults)	4.6 – 13.5 U/g Hb (method-dependent)	Decreased (<4.0 U/g Hb) indicating mild, moderate, or severe deficiency.
G6PD Enzyme Activity (Newborns)	10.0 – 20.0 U/g Hb (physiologically higher)	Significantly reduced activity indicating congenital G6PD deficiency.
Hemoglobin (Hb) Level	Male: 13.8 – 17.2 g/dL; Female: 12.1 – 15.1 g/dL	Decreased during acute or chronic hemolytic episodes (anemia).
Reticulocyte Count	0.5% – 2.5% of total red blood cells	Elevated (>2.5%) indicating bone marrow compensation for hemolysis.
Total & Indirect Bilirubin	Total: 0.2 – 1.2 mg/dL; Indirect: <0.8 mg/dL	Elevated indirect bilirubin reflecting active erythrocyte destruction.
Serum Haptoglobin	30 – 200 mg/dL	Markedly decreased or undetectable during intravascular hemolysis.
Plasma Free Hemoglobin	<5 mg/dL	Elevated during acute intravascular hemolytic events.
Heinz Bodies (Special Stain)	Absent	Present on peripheral blood smear during active oxidative stress.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Blood G6PDH (Quantitative)?

• Experienced Healthcare Professionals: Chughtai Lab employs highly qualified consultant pathologists, hematologists, and laboratory technologists who oversee all testing procedures.
• Patient-Focused Care: The laboratory is dedicated to providing compassionate, patient-centric services, ensuring a comfortable and stress-free testing experience.
• Quality Diagnostic Services: Utilizing state-of-the-art automated clinical chemistry and hematology analyzers to deliver highly accurate and reproducible quantitative results.
• Professional Reporting: Reports are structured clearly, providing comprehensive reference ranges and pathological interpretations to assist clinicians in decision-making.
• Modern Diagnostic Approach: Continuous integration of advanced diagnostic methodologies and strict adherence to international quality control standards.
• Comfortable Environment: All collection centers are designed to meet high standards of hygiene, safety, and patient comfort.
• Convenient Location: With an extensive network of collection centers across Pakistan, patients can easily find a Chughtai Lab facility nearby.
• Commitment to Accurate Diagnosis: Participation in external quality assurance programs ensures that every test result meets global standards of diagnostic excellence.